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Summary
The 12th Stock Conference addressed body composition and related
functions in two extreme situations, obesity and cancer cachexia. The
concept of ‘functional body composition’ integrates body compo-
nents into regulatory systems relating the mass of organs and tissues
to corresponding in vivo functions and metabolic processes. This
concept adds to an understanding of organ/tissue mass and function
in the context of metabolic adaptations to weight change and disease.
During weight gain and loss, there are associated changes in individ-
ual body components while the relationships between organ and
tissue mass are ﬁxed. Thus an understanding of body weight regula-
tion involves an examination of the relationships between organs and
tissues rather than individual organ and tissue masses only. The
between organ/tissue mass relationships are associated with and
explained by crosstalks between organs and tissues mediated by
cytokines, hormones and metabolites that are coupled with changes
in body weight, composition and function as observed in obesity and
cancer cachexia. In addition to established roles in intermediary
metabolism, cell function and inﬂammation, organ-tissue crosstalk
mediators are determinants of body composition and its change
with weight gain and loss. The 12th Stock Conference supported
Michael Stocks’ concept of gaining new insights by integrating
research ideas from obesity and cancer cachexia. The conference
presentations provide an in-depth understanding of body composi-
tion and metabolism.
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Introduction
From organ and tissue masses to functional
relationships between organs and tissues
Manfred J. Müller
Although anatomy is central in medicine, it is only recently
that the relationships between body composition and meta-
bolic and functional characteristics came into the focus of
research. During the last 20 years, there were fascinating
methodological and technical achievements in in vivo
assessment of body composition and major whole-body
components have been characterized at different levels, i.e.
the whole body (body mass) to tissues and organs (adipose
tissue, brain, liver, skeletal muscle, bone), cells (fat and
non-fat cell mass, extracellular mass, extracellular solids),
molecular (fat, protein, minerals, water) and elements (e.g.
whole-body nitrogen and carbon content; (1)). The descrip-
tive concepts have been extended to the concept of func-
tional body composition that integrates body components
into regulatory systems by relating body components to
their corresponding in vivo functions and metabolic pro-
cesses (2). Suitable applications of body composition analy-
sis are (i) interpretation of body functions (e.g. fat-free
mass [FFM] as the major determinant of energy expendi-
ture) and their disturbances in the context of body compo-
nents (e.g. insulin resistance related to ectopic fat
accumulation in liver, skeletal muscle and pancreas) and
vice versa; and (ii) interpretation of the meaning of indi-
vidual body components in the context of their functional
consequences (e.g. adaptation of energy expenditure to
weight loss is related to fat mass [FM] and body water).
Accurate tools can now be used to assess body compo-
sition for risk prediction, ‘phenotyping’ the obese as well as
the malnourished patients and their related comorbidities
(3). Individual body components such as FM are under
hormonal and genetic control; they are also affected by
environmental factors, lifestyle and diseases. Regulation of
body weight is a multiple (and at least in part) integrated
control of individual body components. Because body com-
ponents are interrelated and the relationships between indi-
vidual body components are stable with weight changes,
control of body weight seems to be on relationships
between tissues and organs rather than on individual com-
ponents or masses themselves.
Evidence for the idea comes from Benedict’s early starva-
tion experiments as well as Keys’ seminal semi-starvation
study, which both have been re-analysed more recently (4–6).
In these studies, the ratio between losses in FM and losses in
FFM remained constant throughout a longitudinal weight
loss protocol. There was some inter-individual variance in the
so-called P-ratios (i.e. the ratio of protein energy mobilized to
total energy mobilized) and baseline body composition was
shown to be its major determinant (7,8). These coordinated
changes in organ and tissue masses in response to caloric
restriction go in parallel with mass- and tissue-independent
changes in their speciﬁc metabolic rates (9).
Faced with the stable relations between individual
organs, inter-organ and inter-tissue crosstalks are challeng-
ing area of research. The present discussion is mainly about
crosstalks of adipose tissue with other organs such as skel-
etal muscle, liver and brain brought about by a still increas-
ing number of secretory products derived from the
adipocyte. In addition, liver, skeletal muscle, kidney, bone,
immune cells and the gastrointestinal tract have also been
characterized as endocrine organs with a huge number of
secretory products contributing to various between-organ
and tissue crosstalks and feedback control signals.
As for concepts, crosstalks may have different functional
characteristics. In electronics, a crosstalk is characterized
by an interaction of signals (10). Then, a crosstalk may
happen at the near end such as between different fat depots
and skeletal muscle. Alternatively, a sum near end crosstalk
brings together multiple adjacent pairs such as the sum of
signals generated in adipose tissue, muscle or immune cells
acting on endothelial cells. In addition, a far end crosstalk
interferes between a peripheral organ and tissue and a
central control unit, e.g. between adipose tissue and the
hypothalamus. Crosstalks may also be attenuated or com-
pensated as might occur with the generation of brown fat
cells within white adipose tissue (WAT) as related to and
affects the adipose tissue–skeletal muscle crosstalk. Finally,
there may be interferences between different crosstalks as
in the case when muscle-adipose tissue crosstalk interferes
with the muscle-bone crosstalk.
It is challenging to discuss these new concepts in two
opposite situations, obesity and cachexia. The feature
common to both is perturbation in energy balance. As
Stock and others have already noted, both areas may
provide possibilities for an integrated approach (11). Inte-
gration of research ideas and joint discussion of similarities
and extremes will beneﬁt future understanding and
research in obesity and cachexia (11,12). If present, a
malignant tumour adds an additional dimension both in
terms of the speciﬁc metabolic rate of the tumour mass as
well as its secretory products which may override normal
physiological controls (see Cachexia section).
Concepts
A model of functional body composition in humans
Kevin D. Hall
Dynamic changes in functional body composition result
from an imbalance between the metabolizable energy
content of the diet and the body’s energy demands. More
speciﬁcally, body composition changes at the chemical
level result from imbalances between the macronutrients
absorbed from the diet and the metabolic fuels oxidized to
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meet energy requirements. Because energy expenditure and
metabolic fuel utilization are both strongly inﬂuenced by
body composition, there results a complex dynamic inter-
play between these variables.
Mathematical modelling provides a useful approach to
dealing with this complexity (8). These models can be
envisioned by analogy to a ‘ﬂex-fuel automobile’ that can
run on an arbitrary mixture of different fuels (as it occurs
in humans with carbohydrate, protein and fat). Such a
‘ﬂex-fuel vehicle’ would allow the driver to ﬁll the tank
with whatever fuel that was cheaper or more readily avail-
able, regardless of what mixture is already in the tank.
Designing such a vehicle would be a signiﬁcant engineering
challenge, but imagine how much more difﬁcult it would be
if the vehicle was not allowed to have a fuel tank. Rather,
the vehicle itself must be composed of its fuel and would be
continually breaking down and reconstructing its compo-
nents. Despite the daily turnover of its components and
ﬂuctuations of fuel delivery, the composition of the vehicle
must remain relatively stable and maintain similar perfor-
mance characteristics. The human body accomplishes this
remarkable engineering feat by the use of three dietary
macronutrients (carbohydrate, protein and fat) to both fuel
metabolism and provide substrates for body constituents.
While the physiological mechanisms underlying the regu-
lation of human macronutrient metabolism and body com-
position dynamics are exceedingly complex, the whole-
body system obeys thermodynamic laws that make the
overall system amenable to mathematical modelling. These
conservation constraints form the basis of mathematical
models that relate macronutrient imbalances between
dietary intake and metabolic utilization with changes in
stored glycogen, protein and fat. The changes in these
chemical constituents and the ﬂuid shifts associated with
these changes allow for mathematical models of functional
body composition dynamics at multiple levels of organiza-
tion ranging from the chemical to tissue and organ levels.
Model predictions have been validated against the data
from independent-controlled feeding studies in humans
(4,5,13,14) and were found to match the model predictions
(8,15,16). This was not only true for prediction of weight
and body composition changes, but also resting energy
expenditure (REE), carbohydrate and fat oxidation, nitro-
gen balance, and individual substrate ﬂuxes, e.g. de novo
lipogenesis, protein degradation, and synthesis, as well as
gluconeogenesis (13–17). This can be extended by taking
into account metabolic adaptations, i.e. the thermic effect
of feeding, adaptive thermogenesis in response to under-
feeding, and the effects of physical activity and exercise on
energy expenditure and substrate oxidation rates. Applying
models to available experimental data allows for explora-
tion of unaccounted for variance and the potential to infer
unmeasured quantities and reveal new metabolic ﬁndings
(18).
Simpliﬁcation of complex macronutrient balance models
can be achieved by quantifying how energy imbalances are
partitioned between either FM or FFM (or body protein)
during weight loss and weight gain, and most models of
human body composition dynamics have used such simpli-
ﬁcations (8). It is also possible to derive energy partitioning
relationships between different body fat compartments. For
example, visceral adipose tissue (VAT) changes as fraction
of the change in whole-body FM is strongly correlated with
the initial VAT/FM ratio (19). Data suggest that there is a
preferential loss in VAT with a higher initial VAT/FM ratio
and that the same allometric relationship describes the VAT
response to exercise, diet, diet + exercise, and weight loss
after bariatric surgery in both men and women.
Dynamic mathematical models provide an integrative
framework to help design, predict and interpret the results
of human experiments and in clinical practice. For
example, modelling weight loss in response to diet and
exercise provides a sound basis in treating obese patients
(17). Furthermore, mathematical modelling is beginning to
help better understand the metabolic and body composi-
tion derangements that occur in diseases such as cancer
cachexia (20).
Regulation of body composition: body
components–brain feedback in weight control
Abdul Dulloo
The regulation of body composition in response to energy
deﬁcit and energy surplus can be conceptualized as being
brought about through control systems that operate via the
control of body energy partitioning between lean and fat
tissues, via compensatory changes in energy intake and via
adaptive changes in thermogenesis. Despite considerable
advances made over the past decades towards establishing
the existence and operational modes of these control
systems, a mechanistic explanation of body composition
regulation in humans remains largely fragmentary. Funda-
mental questions have been raised and addressed from the
analysis of data from longitudinal studies of experimentally
induced weight loss/recovery or weight gain/recovery.
These ﬁndings have been integrated into conceptual models
of body composition autoregulation and they pinpoint
some of the important issues and gaps in knowledge about
various components of feedback loops between changes in
body composition and compensatory changes in energy
intake and energy expenditure (6,21,22).
For example, the adipocyte-releasing hormone leptin –
which acts on brain areas to induce satiety and enhance
sympathetic control of thermogenesis – is often integrated
in the lipostatic theory of weight regulation. Yet, the role of
leptin as a circulating ‘adipostatic’ signal controlling body
fat is questionable in view of the poor correlation between
the kinetics of circulating leptin and dynamic changes in
body fat in response to energy deprivation and refeeding.
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Furthermore, a feedback loop between body fat depletion
and the brain circuitries controlling food intake cannot
alone explain why human subjects recovering weight after
starvation continue to overeat well after body fat has been
restored to pre-starvation values, thereby resulting in ‘fat
overshooting’. Indeed, a detailed re-analysis of the classic
Minnesota Experiment of semi-starvation and refeeding
suggests that the autoregulatory component of the
hyperphagic response to energy deprivation goes beyond an
explanation based solely on the lipostatic theory because,
in addition to the depletion of FM, the reduction in FFM
also contributes to the compensatory hyperphagia (23).
The integrated outcome of this re-analysis suggests that
the critical event that eventually leads to the prolongation
of hyperphagia beyond the complete recovery of FM
resides in the suppression of thermogenesis which drives fat
recovery at a rate that is greater than that determined by
the partitioning characteristic of the individual (24). As this
enhanced metabolic efﬁciency that drives fat acceleration is
a function of fat depletion, and the prolongation of hyper-
phagia (after complete recovery of FM) is a function of
depleted FFM still to be recovered, the extent of fat over-
shooting would therefore depend upon the extent to which
both FM and FFM are depleted. This, in turn, would
depend upon the partitioning characteristic of the individ-
ual which is known to be dictated primarily by the initial
(pre-starvation) adiposity. Indeed, the extent of fat over-
shooting can be shown to increase exponentially with
decreasing initial %body fat (22). From a perspective of
autoregulation of body composition therefore, lean dieters
are at greater risk for fat overshooting than the obese
dieters. Given the increasing prevalence of dieting among
those in the normal weight range (due to pressure for a slim
image, body dissatisfaction or athletic performance),
together with accumulating evidence suggesting increased
cardiometabolic risks associated with weight ﬂuctuations
in the non-obese population groups (25), the notion that
large ﬂuctuations in body weight may predispose to
increased fatness and the metabolic syndrome warrants
greater experimental scrutiny and deserves greater public
health concern than so far acknowledged.
Overall, the available evidence suggests that feedback
signals from both fat and lean tissues operate in the regu-
lation of body composition through their central effects on
food intake and thermogenesis, although the various key
components of these adipostatic and proteinostatic feed-
back mechanisms remain undeﬁned. However, the discov-
ery that a multiplicity of factors are secreted by adipocytes
and myocytes opens new avenues in the search for
adipostatic and proteinostatic feedback signals to the brain
in the regulation of body composition, with major impli-
cations for the pathogenesis and management of obesity
and cachexia. Furthermore, there is emerging evidence of a
role for brain–muscle interactions in the mechanisms by
which inﬂammatory signals mediate the loss of skeletal
muscle mass during cachexia. In addition to the direct
effects of inﬂammatory cytokines in inducing skeletal
muscle atrophy, the integration of inﬂammatory cytokines
signalling pathways within the central nervous system has
been shown to play a critical role in muscle wasting via
activation of the hypothalamic–pituitary–adrenal axis (26).
Future investigations along such brain–muscle interactions
are bound to provide powerful insights into the mecha-
nisms of muscle wasting during cachexia and in the patho-
genesis of sarcopenic obesity.
What is an appropriate energy expenditure for
body composition?
Steven B. Heymsﬁeld
Determining if a subject’s REE is low or high for its body
size is a pervasive question in clinical nutrition research
(27,28). High or low REE values can signal variance in the
composition of FFM (i.e. the relative proportion of high,
metabolic rate organs such as brain, heart, liver and
kidneys), underlying metabolic disease, predisposition to
weight gain or loss, or metabolic processes that are unre-
lated to body size. Early investigators applied body mass
and height as size measures, all that they had available at
the time, and formulated the surface law (REE∝Mass0.66)
and Kleiber’s law (REE∝Mass0.75), although each has limi-
tations when adjusting REE (29).
Body composition methods ﬁrst developed and then
introduced during the mid-20th century provided the ﬁrst
opportunity to identify ‘homogeneous’ metabolically active
compartments (29). REE is highly correlated with the body
size composition measures and the adjusted value of REE
should be independent of body size. Consider the simple
regression model,
REE FFM= +m b, (1)
with m being the slope and b (REE) the y-axis intercept. For
the ratio REE/FFM to be independent of FFM, the y-axis
intercept must be zero so that
REE FFM and thus= m , (2)
REE FFM (3)
is a stable value (i.e. m) across all healthy adults. In fact,
when REE is regressed against FFM, the b intercept term is
positive and differs signiﬁcantly in magnitude from zero.
REE for men and women plotted against FFM results in a
regression line with a signiﬁcant intercept term of
410.4 kcal d–1 (27,29).
FFM has remained the main compartment used by
investigators over the past several decades to adjust REE
for body size (27,28), although the need to remove low
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metabolic rate compartments other than fat from body
mass as a means of estimating ‘metabolically active’ body
mass was recognized.
At the tissue-organ level, the present availability of esti-
mates of organ and tissue masses provided a new opportu-
nity to develop physiological REE prediction formulas
based upon established heat production rates of major
body tissues (9,30,31). Tissue and organ mass can be esti-
mated with great accuracy using computed tomography
(CT) or magnetic resonance imaging (MRI); the energy
expended by each tissue and organ can be calculated as the
product of mass and mass-speciﬁc metabolic rate based on
compiled from in vivo and in vitro observations. REE can
be calculated as the sum of all tissue and organ metabolic
rates. Viewing REE from the tissue–organ perspective, the
large contributions of four FFM components (brain, liver,
heart and kidneys) to whole-body REE become obvious.
While <6% of representative body mass, these organs con-
tribute to 60–70% of REE. REE is then calculated from
REE kcal d 24 brain mass liver mass
44 heart mas
−( ) = ×( ) + ×( )
+ ×
1 0 200
0 s 44 masses
of kidneys mass of skeletal
muscle b
( ) + ×(
) + ×(
) + ×
0
13
2 3. one mass
adipose tissue mass
residual mass
( )
+ ×( )
+ ×( )
4 5
12
.
.
(4)
Residual mass is the difference between the sum of meas-
ured body components and body weight. Today, physio-
logical REE model terms for brown fat and the microbiome
are not yet available.
Tissue–organ proportions vary with body size (i.e.
among normal-weight, overweight and obese subjects), in
adolescents and adult age, across men and women, between
race groups, and with stature (29,30,32). All tissues and
organs scale to FFM with powers approaching 1.0, except
brain, which has powers <0.2 for both men and women
(29). Multiple regression analysis was used to establish
how skeletal muscle, heart, liver, kidney, brain and residual
mass (weight minus the sum of other tissues, including
adipose tissue and organs) scale to FFM. Tissue–organ
mass was set as the dependent variable and FFM, age and
adipose tissue mass as potential predictor variables in
multiple regression models. The explained variance of tra-
ditional REE model with FFM alone as the predictor was
0.78 and SEE = 129.4 kcal d–1. Adding age and adipose
tissue mass increased R2 to 0.84 (SEE, 112.2 kcal d–1).
All these models had statistically signiﬁcant intercepts
and they resemble the general form of traditional FFM-
based REE prediction models (29). However, brain, liver,
skeletal muscle, bone, adipose tissue, residual mass and age
added as signiﬁcant covariates and the ﬁnal R2 reached
0.86 with lowest SEE (105.9 kcal d–1) of the developed
series of REE prediction models with a non-signiﬁcant
intercept of 40.6 kcal d–1. Because REE links to tissue-
organ level, the traditional REE-FFM model given in
formula (1) is converted into
REE kcal d AT Br Li
SM RM A
−( ) = + + +
+ + −
1 40 6 5 1 294 2 141 5
20 3 13 7 1 6
. . . .
. . . ge.
(5)
The newly deﬁned compartments have improved correla-
tions with REE estimates over body weight-height
approaches, but all share a common limitation: REE-body
composition ratios are not ‘constant’ but vary across men
and women and with race, age and body size (27,28). The
currently accepted alternative to ratio-based norms is to
statistically adjust for predictors by applying regression
models to calculate ‘residuals’ that determine if a measured
REE is relatively high or low (27,28).
The distinguishing feature of statistical REE-body com-
position models is a ‘non-zero’ intercept, the cause of which
is unknown. FFM is not a metabolically homogeneous
compartment, but instead FFM varies systematically in
tissue–organ proportions as a function of body size. The
non-zero intercept observed with traditional REE models
largely becomes non-signiﬁcant when organ volumes (e.g.
brain and/or liver mass) are included as model covariates
(29). These new ﬁndings provide a context for future
research aimed at establishing between subject differences
in energy metabolism. To go beyond the whole body or
tissue/organ mass is to directly measure speciﬁc energy
expenditure of individual tissues and organs as well as their
changes in response to changes in weight and body com-
position (9,31). These advances will likely improve our
understanding of energy expenditure effects of disease,
including cancer and other chronic conditions associated
with cachexia.
Functional aspects of adipose tissue and muscle
Effects of over- and under-nutrition on body composition
and metabolism of the mouse – what goes up does not
necessarily come down
John Speakman
When animals consume excess calories they gain weight,
and when they consume insufﬁcient calories relative to
expenditure they lose weight. However, these gross changes
in body weight mask the details of the changes in body
composition that accompany the responses to over- and
under-nutrition. These relations were studies in adult mice
(5 months old) with stable body weights who were fed two
graded levels of over-nutrition (high-fat diets with differing
% fat up to 60%) and ﬁve graded levels of caloric restric-
tion (from 0 to 40% less calories than their individual
baseline intakes). As anticipated, greater over-nutrition led
to greater total body weight gain and greater levels of
under-nutrition led to greater levels of body weight loss.
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The changes in 23 tissues assessed, however, were radi-
cally different. When animals gained weight they did so
primarily by increasing the sizes of their fat stores in dif-
ferent body regions (i.e. subcutaneous, epididymal,
retroperitoneal, omental, mesenteric and brown adipose
tissue). The sizes of the vital organs (i.e. brain, liver,
kidneys, heart, lungs, pancreas and spleen) were unaffected
but structural organs (bone and skeletal muscle, pelage and
tail) also increased in size.
During weight loss with caloric restriction, there was
also a loss in body fat, but the largest weight losses were
actually among structural organs – such as the skeletal
muscle, skin and tail. The vital organs were also generally
decreased but to a lesser extent than structural organs or
fat. Testes mass decreased at the highest level of caloric
restriction only, whereas the mass of accessory organs
such as seminal vesicles linearly decreased with the degree
of starvation. Some vital organs related to the alimentary
tract (i.e. stomach, small intestine, caecum, large intestine)
actually increased or remained unchanged in size under
restriction.
Calculations reveal that tissue loss contributes to about
20% of the energy shortfall explaining 52–81% of the
reduction in whole-body energy expenditure. This is asso-
ciated with decreases in circulating IGF-1 and resistin
levels.
Two hypotheses emerge about the implications of organ
and tissue mass loss during caloric restriction. First,
animals oxidize the energy derived from those tissues.
Second, reducing organ-tissue mass lowers energy expendi-
ture and thus contributes to metabolic adaptation. These
changes reﬂect the functional responses of the animals that
attempt to minimize expenditure while preserving vital
functions and sustaining food intake.
With overfeeding, weight gain is mostly explained by
expansion of WAT. In addition, there were small changes in
structural body components. By contrast, masses of vital
organs and brown adipose tissue remained unchanged.
Functional correlates of fat mass and fat-free mass
relationships during underfeeding and refeeding
in humans
Anja Bosy-Westphal
Short-term voluntary perturbations in energy balance lead
to metabolic and neuroendocrine adaptations that counter-
act weight changes. For example, regain of weight and FM
may exceed prior weight loss, the so-called ‘catch-up fat
phenomenon’ (5,23). Fat regain at an intense rate can also
occur in patients with cancer cachexia during short-term
remission of their disease, suggesting that the impetus for
catch-up is also present in disease (33). Adaptive
thermogenesis and reduced energetic efﬁciency of physical
activity add to compensate body weight whereas insulin
sensitivity and a low metabolic ﬂexibility contribute to the
partitioning of weight regain (i.e. as gain of either FM or
FFM (34,35)). Beyond energy and macronutrient balances,
diet composition (e.g. glycaemic load; glycaemic index (GI);
protein content) contributes to these adaptations.
When compared with high GI diets with a lower protein
content, a low GI diet with a higher protein content
resulted in improved weight loss maintenance in weight-
reduced obese patients (36). These ﬁndings point to insulin
secretion and/or insulin sensitivity as determinants of
weight gain. However, insulin sensitivity had no effect on
weight gain (37), but in Pima Indians insulin resistance was
associated with reduced risk of weight gain (38). By con-
trast, improved insulin sensitivity with energy restriction
was associated with lower weight regain after previous
weight loss (39).
Using a controlled dietary intervention study protocol to
investigate whether diets differing in carbohydrate content
and GI affect regain in fat and FFM under conditions of
ﬁxed energy intake and physical activity, 32 healthy, nor-
mal-weight, young men followed 1 week of overfeeding
protocol (mean weight gain of 1.8 kg), 3 weeks of caloric
restriction (mean weight loss of about 6.0 kg) and 2 weeks
of hypercaloric refeeding at ±50% energy requirement
(mean weight regain of 3.4 kg; for details, see 40–43).
During refeeding, four study groups differing in carbohy-
drate intake (50%CHO, 65%CHO) and GI (low GI, high
GI) were formed. Changes in FM were measured by quan-
titative magnetic resonance (EchoMRI; Houston, TX, USA;
43) and adjusted for predicted values using mathematical
modelling of energy balance (15).
Both GI and carbohydrate content affected insulin sen-
sitivity, metabolic ﬂexibility (i.e. the increase in respiratory
ratio [RQ] with refeeding, and thus the capacity to utilize
lipid and carbohydrate fuels and to transition between
them; 44), and the partitioning of weight regain. Refeeding
was associated with impaired fasting fat oxidation and thus
augmented fat regain. Energetic efﬁciency at low work
intensities was reduced in response to caloric restriction.
The higher the fall in energetic efﬁciency during low-level
exercise, the greater the regain of body weight.
As to the determinants of weight regain, (i) decreases in
plasma leptin levels, (ii) reduced energetic efﬁciency at low
work intensities during preceding caloric restriction, as
well as (iii) a limited activation of the sympathetic nervous
system (SNS) with refeeding were signiﬁcantly associated
with regain in body mass. Weight regain as either FM or
FFM was associated with a reduced insulin sensitivity and
low metabolic ﬂexibility during refeeding (40,41).
Taken together, during caloric restriction, the decrease in
plasma leptin levels, the increase in energetic efﬁciency at
low-grade physical activity, and a relatively low SNS activ-
ity are associated with regain in body weight during sub-
sequent refeeding. During refeeding, insulin resistance and
a low-fat oxidation add to regain of FM.
6
ht
tp
://
do
c.
re
ro
.c
h
Skeletal muscle crosstalk in response to exercise
and nutrition
Jürgen Eckel
Regular physical activity has beneﬁcial effects on whole-
body metabolism, while a sedentary lifestyle is a major risk
factor for developing metabolic diseases such as type 2
diabetes mellitus. Besides their established roles in work
performance, energy and protein stores, skeletal muscle
and adipose tissue are endocrine organs. Skeletal muscle
cells and adipocytes both secrete a broad range of proteins
and cytokines, generally termed adipokines in the case of
adipocytes, and myokines for muscle cells. Myokines have
been shown to affect muscle physiology and additionally
exert systemic effects on other tissues and organs.
Several myokines are regulated by contraction, such as
angiopoietin-related protein 4, ﬁbroblast growth factor 21,
interleukin (IL)-6, IL-7, IL-15, leukaemia-inhibitory factor,
myonectin, myostatin and vascular endothelial growth
factor (VEGF) (45). The beneﬁcial effects of physical activ-
ity are often considered due to an improved energy metabo-
lism; however, myokines are also thought to be involved
because skeletal muscle secretes higher levels of myokines
in response to contraction (45).
With contraction, muscle glucose uptake and fat oxida-
tion rates increase, and these effects are associated with the
release of myokines such as IL-6, IL-7 and BDNF (brain-
derived neurotrophic factor). Until now, there are more
than 540 myokines, and IL-6 is the most prominent
muscle-derived protein, which was demonstrated to be
up-regulated in plasma after exercise (46). By contrast,
contraction blocks TNFα release and signalling in muscle.
As IL-6 and BDNF result in increased lipid oxidation, IL-7
regulates muscle cell development. Novel contraction-
regulated myokines are YKL-40, irisin and MCP-1.
Many of the contraction-regulated myokines described
in the literature are additionally known to be secreted by
adipocytes. These proteins were termed adipo-myokines.
The current literature mainly describes a negative crosstalk
between excess body fat and skeletal muscle, while the data
of IL-6 and irisin indicate an additional crosstalk from the
muscle to the adipose tissue (47,48).
Adipokines and myokines appear to have autocrine
effects within skeletal muscle and adipose tissue. Addition-
ally, they are involved in an endocrine crosstalk with other
tissues such as liver. Depending on the serum level and the
incubation time, adipo-myokines appear to have a beneﬁcial
or an adverse effect on the target tissue (49). Adipokines and
myokines may also have inconsistent effects. It is presently
unclear why pro-inﬂammatory adipokines are up-regulated
in the obese state, and thus may be associated with negative
sequelae even though they also have beneﬁcial effects after
exercise.
Myokines have been proposed to increase energy expendi-
ture, an effect explained by the development of brown-fat-
like cells of white adipocytes (47). At the cellular level, the
transcriptional co-activator, PGC1alpha, activated by
FGF21 (ﬁbroblast growth factor) generated in brown
adipocytes, stimulates glucose uptake, lipolysis and meta-
bolic rate. PGC1alpha expression in muscle increases the
expression of FNDC5, a membrane protein that is cleaved to
the myokine irisin. Irisin is induced in mice but its existence
in humans is questionable (48). In contrast to mice, FNDC5
is not up-regulated by contractile activity in humans and
irisin was not found in supernatants of human myotubes
(48). Genome analysis revealed that irisin is a pseudogene in
humans, the protein is not translated due to a mutation in
the start codon. In addition, irisin had no effect on the
white-to-brown transition of human pre-adipocytes.
More recently, a novel cytokine, YKL-40 (also known as
Chitinase-3-like protein1, CHI3L1), has been identiﬁed in the
secretome of primary human skeletal muscle cells by mass
spectroscopic analysis. This protein is expressed by many
other cells (e.g. macrophages and hepatocytes). It lacks enzy-
matic activity and binds to PAR2 (protease-activated recep-
tor2). YKL-40 secretion goes down during differentiation and
is up-regulated by inﬂammatory cytokines. YKL-40 reduces
(i) TNFα but not IL-1beta-induced NF-kB activation, and (ii)
the TNFα-mediated secretion of MCP1, IL-8 and IL-6 secre-
tion. In addition, YKL-40 protects from TNFα-mediated
insulin resistance. Taken together YKL-40 reﬂects the versa-
tility of an individual myokine.
Adipokines, myokines and tissue crosstalk
Paul Trayhurn
WAT, which was traditionally considered to have little or
no function beyond that of a fuel storage organ, is now
recognized to have multiple roles. These include thermal
insulation (particularly in marine mammals), mechanical
protection, and as a key signalling and endocrine organ.
Our current perspective on the physiological roles of white
fat follows from the discovery that white adipocytes are
major secretory cells, releasing a multiplicity of metabolic
and signalling factors (50–54). Adipocyte secretions, the
quantitatively most important of which are fatty acids,
comprise both lipids and proteins. Most attention has been
focused on the protein factors secreted from fat cells – the
adipokines. Nevertheless, there is a range of lipid moieties
released from white adipocytes, and these include prosta-
glandins, endocannabinoids, α-tocopherol, cholesterol and
the active form of vitamin D3 (51,52).
More than 100 different adipokines have been clearly
identiﬁed based on gene expression, and the demonstration
that the encoded protein is secreted from adipocytes.
However, proteomic studies indicate that there are several
hundred adipokines in total (55). Many adipokines are linked
to immunity and the inﬂammatory response (including both
classical cytokines and chemokines), to insulin sensitivity, and
to the architecture of the extracellular matrix of adipose tissue
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(53–56). Others are involved in lipid metabolism, vascular
haemostasis, the regulation of blood pressure or energy
balance. Much attention has been focused on inﬂammation-
related adipokines and the state of inﬂammation that devel-
ops in adipose tissue as tissue mass expands in obesity (53).
This inﬂammatory state, which involves the recruitment of
macrophages and other immune cells, as well as the increased
synthesis and release of inﬂammation-related adipokines, is
widely considered to underpin the development of obesity-
associated disorders – particularly insulin resistance and the
other components of the metabolic syndrome (53–56).
Two particular adipokines – leptin and adiponectin – are
major hormones that were ﬁrst discovered in adipose tissue
and which have multiple actions, both locally and distally.
Indeed, it was the discovery of leptin in 1994 as the product
of the ‘ob’ (now LEP) gene, a mutation that leads to the
profound obesity of the ob/ob mouse, that has led to the
unambiguous recognition of WAT as an endocrine organ
(57). Some adipokines may function locally, through
autocrine or paracrine actions, rather than being endocrine
factors. By deﬁnition, endocrine factors secreted from
adipocytes are involved in communicating with other
tissues and organs. One of the most potent examples of the
endocrine action of an adipokine comes from the central
effects of adipocyte-derived leptin on the neuroendocrine
regulation of appetite in the hypothalamus. This demon-
strates a direct communication from fat cells to the brain.
While the synthesis and secretion of many key
adipokines, including leptin and inﬂammation-related
factors such as IL-1β and IL-6, rise with increasing adipose
mass in obesity, the production and release of the other
major adipocyte hormone, adiponectin, falls (58,59).
Importantly, this has implications for inﬂammation and
insulin sensitivity because the hormone has both anti-
inﬂammatory and insulin-sensitizing actions (60–62). One
of the conundrums in adipose tissue biology is why the
production of many adipokines changes with tissue expan-
sion in the obese. One proposed mechanism is that it is a
response to hypoxia, mouse data demonstrating clearly
that the O2 tension is markedly lower in adipose tissue
depots of obese than lean animals (51,63). Hypoxia may
underpin the inﬂammatory response and other functional
changes in adipocytes that occur with obesity. Indeed, in
adipocytes in culture, reduced O2 tension leads to the
stimulation of the expression and release of adipokines
such as leptin, VEGF, IL-6 and angiopoietin-like protein 4/
fasting-induced adipose factor (ANGPTL4), while inhibit-
ing the production of adiponectin (63).
The identiﬁcation of the rapidly growing family of
adipokines has revolutionized our understanding of the
biology of WAT and the extent to which it is integrated into
metabolic regulation and whole-body homeostasis. It has
also increasingly served as a model for other tissues and
organs which had not been previously considered to exhibit
a signiﬁcant secretory function. Perhaps the most potent
example is skeletal muscle. While myostatin (also known as
growth differentiation factor 8) had been recognized as a
secretion from myocytes, inhibiting muscle differentiation
and growth, the possibility that there is a range of protein
secretory products from muscle cells appeared unlikely.
However, the perspective began to change following the
discovery that skeletal muscle releases large quantities of
IL-6 into the circulation following exercise (64–67). Muscle
contraction leads to the stimulation of the expression of the
IL-6 gene in muscle cell cultures and the encoded protein is
released. This has led to the development of the concept of
myokines as secreted proteins from muscles, paralleling the
adipokine paradigm.
Subsequent studies, taking in effect a candidate gene/
protein approach, have identiﬁed several other myokines,
including IL-7, Il-8, IL-15, chemokine CXC motif ligand-1
(CXCL-1) and leukemia inhibitory factor (LIF) (65,67–69).
This has recently also been followed by proteomic appro-
aches in which the muscle protein secretome has been inves-
tigated. Proteomics suggests that the number of myokines
may be in the low hundreds (70–72), although caution has to
be exercised in that there is the risk that cell damage leads to
the leakage of proteins into the culture medium which would
not otherwise be released – similar caution needs to be
considered in the case of proteomic studies on adipocytes.
Nevertheless, it is increasingly evident that the myokines as a
group are not restricted to a small number of proteins. A
recently identiﬁed myokine of particular interest is irisin. This
is encoded by the skeletal muscle ﬁbronectin domain contain-
ing protein 5 (FNDC-5) gene, the immediate product of
which is a membrane protein that is subsequently cleaved and
secreted as irisin (73). Irisin has the intriguing action of
‘browning’ of white adipose depots – i.e. of driving the tissue
towards a thermogenic, energy-dissipating proﬁle (73,74).
However, while this is the case in rodents, as with resistin, the
situation appears different in humans, as noted above in the
previous part of this manuscript.
Irisin provides a strong example of crosstalk between
tissues, and between skeletal muscle and adipose tissue in
particular. A further example is leptin, which has actions on
muscles as well as other organs, including the brain as
noted earlier. There has been some emphasis on the role of
muscle-derived IL-6 as a lipolytic factor, but this is increas-
ingly viewed as an action within muscle itself rather than
distally on adipose tissue (66).
Cachexia
Body composition and clinical course in patients with
cancer cachexia
Vickie Baracos
The cardinal diagnostic criterion of cachexia is the appear-
ance of involuntary weight loss, signalling alteration of the
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normally precise controls that serve to maintain body
weight and body composition throughout adulthood. Skel-
etal muscle wasting is considered the central feature of
cancer cachexia, and a 2011 international consensus of
experts (75) underscored that this muscle loss may occur
with or without concurrent loss of FM. Clinical and basic
research on cancer cachexia has a strong focus on the
aetiology and clinical implications of this muscle loss.
Severe depletion of skeletal muscle, termed sarcopenia
(Greek ‘sarx’ of ﬂesh), is deﬁned as a low level of muscle
associated with statistically signiﬁcant increases in health
risks and an impaired health state (e.g. mortality, pharma-
ceutical drug toxicity, loss of strength and reduced physical
disability (75)). Cut-offs deﬁning sarcopenia and its rela-
tion to risk of mortality which were solved using statistical
approaches have been published for cancer patients
(76,77). Sarcopenia is prevalent in older populations and is
frequently seen in cancer patients. Cancer patients present-
ing with a loss of muscle mass may be underweight, normal
weight, overweight or even obese (76,77).
In clinical practice, sarcopenia may be camouﬂaged by
overweight and obesity and, thus, there is a need of detailed
body composition analysis. Because cancer patients are
routinely followed in clinical practice by CT imaging, there
is a considerable opportunity for detailed quantiﬁcation of
different tissues with high speciﬁcity and precision. CT
imaging has enormous potential within the ﬁeld of body
composition analysis. In clinical practice, abdominal scans
are often available and images can be evaluated at the level
of the third lumbar vertebra where cross-sectional areas of
muscle strongly correlate with whole-body muscle mass.
Using these measures (77) in a prospective clinical study of
cancer patients with body mass index (BMI >30 kg m−2),
survival was about 11 months in sarcopenic cancer patients
compared with 21 months in a group of patients with
normal muscle mass, and this was independent of cancer
site, stage and performance status. This was subsequently
conﬁrmed and expanded (76) in a population cohort of
patients crossing all categories of BMI. Sarcopenia also
predicted poor outcomes of cancer surgery including infec-
tious complications and use of inpatient rehabilitation (78).
Cancer patients with sarcopenia appear unusually prone to
chemotherapy-associated severe toxicity across a wide
array of cancer sites and cancer therapies, and these studies
have been summarized by (79).
An emerging set of ﬁndings relates to the presence of fatty
inﬁltration of muscle, termed myosteatosis. This is detected
as reduced skeletal muscle X-ray attenuation in quantitative
analysis of CT (i.e. between −29 and +29 HU, low attenua-
tion muscle; between +30 and +150 HU, normal attenuation
muscle). Independent of classic prognostic factors in cancer
such as disease stage, site and patient performance status,
low attenuation values in muscle predict increased mortality
(76,80); however, the underlying basis of the fatty inﬁltra-
tion of muscle and its relation to survival remain to be
understood. Myosteatosis is discussed in further detail by
Dr. Fearon in the next section.
Longitudinal studies provide an opportunity to study the
body composition changes of cachexia over time (20,33).
Repeated measurements suggest that tumour progression is
correlated with losses in adipose tissue and muscle mass,
and this would be expected given the high energy demand
of tumour tissue (20,33). The progression of muscle and fat
loss with tumour progression was exponential and appears
similar in different cancers (lung, colorectal, pancreas
cancer, and cholangiocarcinoma) (33), with the exception
that patients with pancreatic cancer had higher overall
incidence and rate of fat loss.
In patients with advanced cancer, the potential for positive
energy balance skeletal muscle anabolism is not well char-
acterized. In a longitudinal study (33), a mixed population
of patients with advanced solid tumours was studied over a
period of ∼12 months, and each interval between two CT
scans (∼3 months) was assessed for loss, gain and stable
behaviour of fat and muscle. The overall frequency of
muscle gain was 15.4% whereas muscle mass was stable in
45.6% of intervals between any two scans, making mainte-
nance or gain of muscle the predominant behaviour. Like-
wise, adipose tissue was stable in 27.1% of intervals and
gain occurred in 24.8% of intervals. These ﬁndings suggest
that cachexia is not an unmitigated trajectory of loss, but
rather a period dominated by the opposing forces of the
cancer (catabolic) and treatment (anabolic) in a context
where controls of body energy balance are functional and
may result in periods of stability and regain, as well as loss.
The clinical course of skeletal muscle wasting in advanced
cancer and the window of possible muscle anabolism were
assessed. Multinomial logistic regression revealed that being
within 90 d (vs. >90 d) from death was the principal risk
factor for muscle loss (odds ratio [OR] = 2.67) and muscle
gain was correspondingly less likely (OR = 0.37) at this time
(33). Thus, a window of anabolic potential exists at deﬁned
early phases of the disease trajectory (>90 d survival) creat-
ing an opportunity for intervention to stop or reverse muscle
wasting. A variety of nutrition therapies (macro- and
micronutrients, branched chain amino acids, leucine,
n3-fatty acids) and drugs (e.g. selective androgen receptor
agonists, antagonists of myostatin, cytokines and protein
degradation) are under investigation to exploit and expand
anabolic potential.
Adipose tissue muscle crosstalk in cancer cachexia
Kenneth C.H. Fearon
Cancer cachexia is multifactorial characterized by an
ongoing loss of skeletal muscle (with or without loss of
FM) that cannot be reversed by conventional nutritional
support (75). The pathophysiology is characterized by a
negative protein and energy balance driven by reduced food
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intake, low physical activity, systemic inﬂammation and
abnormal metabolism. Cachexia in patients with cancer is
characterized by anorexia, increased or decreased energy
expenditure, increased lipolysis, insulin resistance, reduced
protein turnover and reduced physical activity. The degree
of weight loss and the severity of the underlying metabolic
changes are mainly driven by inﬂammation: cancer patients
with a positive acute phase response had a low energy
intake at concomitantly increased REE.
Mediators of cachexia include cytokines, neuroendocrine
hormones and tumour-speciﬁc factors. Presently, it is not
known to what extent tissue crosstalk (via myokines
or cytokines) contributes to these features in humans.
Recent evidence does, however, raise the possibility that
lipotoxicity from increased fatty acids may be important
(81–83). In cachectic cancer patients, macro- and micro-
scopic changes indicate skeletal muscle lipid inﬁltrations.
Mean lipid droplet count in muscle tissue correlated posi-
tively with the severity of weight loss and increases further
with loss of adipose mass in other body compartments (82).
With regard to muscle ﬁbre type, type II ﬁbres are tar-
geted selectively with relative preservation of type I ﬁbres
(84). Protein synthesis and myogenic cell proliferation, and
protein degradation and apoptosis determine muscle mass.
Faced with the clinical features of cancer cachexia, protein
degradation and, thus, the activity of the proteasome is a
driver of muscle wasting. In fact, an increased proteasome
activity and increased autophagy markers in skeletal
muscle have been described in cancer cachexia (84,85). By
contrast, divergent effects on protein synthesis have been
reported with expression proﬁles characterized by 1,750
down-regulated genes but 150 up-regulated genes (85).
However, when compared to healthy controls, muscle
transcriptome was indistinguishable in cancer patients 8
months after tumour resection.
Altered adipocyte metabolism leads to a loss of FM and
adipose atrophy in cancer cachexia. Metabolically, adipose
tissue wasting is characterized by suppressed lipogenesis at
increased lipolysis. A high rate of lipolysis appears to be a
key factor underlying fat loss, while inhibition of adipocyte
development and lipid deposition may also contribute to
the problem (83). This metabolic pattern is partly
explained by reduced substrate supply (in anorectic
patients) and the increase in inﬂammatory markers (such as
cytokines, TNFα, IL-6) as part of a tumour–adipose tissue
interaction. These cytokines are also generated locally in
macrophages reﬂecting a state of chronic inﬂammation.
Zinc-α2-glycoprotein (ZAG), a 43-kDa protein, is
overexpressed in certain human malignant tumours and
acts as a lipid-mobilizing factor to stimulate lipolysis in
adipocytes leading to cachexia (86,87). ZAG mRNA levels
in WAT are positively correlated with weight loss and the
rate of lipolysis. By contrast, leptin mRNA levels are
reduced in WAT of cachectic cancer patients and showed a
negative correlation with weight loss. However, plasma
leptin levels were shown to be decreased or even increased
in cachectic cancer patients.
Fat–muscle crosstalks might be a critical regulator in the
development of cachexia. This is brought about through free
fatty acids, myokines or adipokines. Data derived from a
model of cachexia and lipolysis in tumour-bearing mice with
wild-type adipose tissue triglyceride lipase (Atgl +/+) or
Atgl–/– (i.e. the gene has been ablated) suggested that at
normal plasma free fatty acid concentrations (due to the lack
of triglyceride lipase and thus failing to increase lipolysis),
fat tissue mass was conserved, and muscle wasting and, thus,
cancer cachexia did not occur (83). The mechanism through
which skeletal muscle mass is maintained in the presence of
the systemic mediators is unknown but may involve muscle–
adipose crosstalk through free fatty acids. Until now, there
has been little effort to manipulate the integrative physiol-
ogy of adipose tissue and muscle tissue for therapeutic
weight gain in tumour patients.
Perspectives
Rethinking why obesity develops and why it is harmful
Thorkild I.A. Sørensen
The prevailing conventional ideas about obesity are that it
is a passive reﬂection of a positive energy balance due to an
‘obesogenic’ environment favouring excess food intake and
physical inactivity, eventually leading to an excessive
amount of stored fat that by itself threatens the health. In
other words, obesity results from a passive storage of
surplus energy which may give rise to inﬂammation and
thus comorbidities. This is also reﬂected by the deﬁnition of
obesity and its association with diabetes, cardio- and cer-
ebrovascular diseases, and certain cancers. A more positive
view of FM is that body fat is an energy reserve available
for the future. Then, obesity may be seen as a healthy and
active response to an expected future lack of energy
(88,89). This challenges conventional ideas about obesity.
The ability to store and mobilize triglycerides in
adipocytes is a very efﬁcient and biologically inert way of
securing the energy supplies in the future when needs for
energy cannot be met by available food. Fat storage is
without health problems unless triglyceride stores can be
expanded and have not reached their limits. Excessive
storage of fat (i.e. obesity) may be considered as a conse-
quence of a spurious unopposed signal of expected future
needs of energy that leads to the harmful metabolic effects
when the limits of storage capacity are reached. Weight
gain and overweight happen if the body senses the risk of
possible future shortage of food, although today this nearly
never happens to people living in Western societies. This
unifying theory requires profound revision of the approach
to obesity, which may lead to new modalities of prevention
and treatment of obesity.
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One may ask how and when this sensing occurs, how it
translates into obesity and, ﬁnally, how comorbidity
results. Evidence for sensing future lack of energy as a cause
of overweight comes from experimental data as, for
example, groups of mice develop greater fat stores with a
reduced food supply (90). Sensing may be based on social
conditions and, thus, social insecurity is considered as a
driver. Thus, besides other consequences, any social chal-
lenge also would imply food insecurity in the future. This is
independent of the present food supply. Evidence for this
idea comes from the observation that when compared with
middle and high socioeconomic state, obesity is highly
prevalent in low socioeconomic states and social insecurity.
Faced with the developments of modern societies, a con-
siderable segment of populations, even in rich countries,
live in ﬁnancial and social insecurity. Sensing social insecu-
rity will vary between different age groups and is unlikely
to occur in children where obesity rates also have increased
during the last decades. It is tempting to speculate that in
children, the sensing of insecurity is transferred from their
parents, perhaps by the way they treat them. Another pos-
sibility is that the parental sensing of insecurity is trans-
ferred to the next generation by epigenetic mechanisms
either before or during pregnancy or direct effects on the
fetus. Obviously, there may well be individual genetic dif-
ferences in the sensing and response to the insecurity.
From a biological point of view, it is presently unclear
how sensing of future food shortages is translated into
deposition of triglycerides and, thus, an increase in FM. It
is likely that central-peripheral psycho-neurobiological
mechanisms inﬂuence this process which is ﬁnally charac-
terized by an expansion and renewal of adipocytes (91).
Both the number of fat cells and their size (i) have an upper
limit and (ii) determine the upper limit of weight gain.
Because adaptation of adipocytes and increased storage
may reﬂect different and at least partly independent pro-
cesses, this may explain the development of different forms
of obesity resulting (i) from simple overfeeding or (ii) true
obesity as a disease.
In terms of survival during food shortages, triglyceride
synthesis in adipocytes is beneﬁcial as long as limits of
storage capacity have not been reached. By contrast, when
storage exceeds its limits, this will result in ectopic fat
deposition, insulin resistance and inﬂammation. Then
negative effects on metabolism and health become evident.
Thus, the association between storage of triglycerides and
metabolic disturbances is not directly due to the triglyceride
accumulation, but is explained by factors co-occurring with
it (89). This idea is supported by the ﬁnding that many
obese individuals do not have adverse health effects and
survive until old age (92). As a consequence, the arbitrary
deﬁnition of obesity simply based on BMI cut-offs as well
as comparing FM between different individuals in clinical
practice becomes questionable unless the capacity of fat
storage is taken into account. In conclusion, there is a need
of a redeﬁnition of fat accumulation and obesity faced with
its beneﬁts and harms.
Intrauterine growth retardation, fat and fat-free mass
relation, and metabolic risks in later life
Angelo Pietrobelli
Low birth weight (LBW) and rapid post-natal growth have
been positively associated with obesity in adulthood (for a
detailed description of that concept, see 93–95). Maternal
factors affecting intrauterine development and growth
include age, weight, height, nutrition, stress, smoking,
drugs, infections, endocrine disorders, vascular diseases
and exposure to environmental contaminants. Normal
growth biology involves relationship among hormonal
levels, body composition, growth patterns with gender and
time-sensitive maturation programs. LBW and infants born
preterm reﬂect a stressful intrauterine milieu and demon-
strate a constellation of aberrant developmental trajec-
tories, which are apparent by term equivalent age and
persist into adult life. In fact, when the fetus is exposed to
malnutrition, the organism diverts the limited nutrient
supply for favouring survival of vital organs such as brain
at the expense growth and other organs such as pancreas.
Fetal malnutrition or, in general, a suboptimal uterine envi-
ronment adds to permanent anatomical and functional
changes in various tissues and organs, ultimately leading to
increased risk of metabolic and cardiovascular disease.
Adverse long-term effects may reﬂect a mismatch between
early (fetal and neonatal) conditions and environmental
and nutritional effects in later life (93,94).
The exposure to a different, and sometimes opposite,
environment in intrauterine life affects the expression of
multiple genes involved in different metabolic pathways.
This is partly brought about by epigenetic changes affecting
programming in multiple organs including the liver (95).
Epigenetic alterations have been proposed as one mecha-
nism to mediate the inﬂuence of early life exposures and
gene-environment interactions. These changes alter the
ability to coordinate fat and carbohydrate metabolism,
favouring a shift to a preferential use of fatty acids as an
energy source in order to adapt the organism to the in
utero-reduced nutrient supply. Altogether, these changes
induce adaptations in hypothalamic-lipid sensing mecha-
nisms, ultimately affecting food intake and endogenous
glucose production in post-natal life (94–96).
Intrauterine adverse cues have been related obesity, type
2 diabetes mellitus, and hypertension, disturbances in lipid
metabolism, non-alcoholic fatty liver, asthma, food allergy,
depression and neurobehavioral impairment (96,97).
In high school girls, there is a signiﬁcant and inverse cor-
relation between birth weights and either blood pressure
or blood levels of triglycerides and insulin (98). In addit-
ion, early post-natal nutrition may affect adult health by
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altering gut microbiota with long-lasting effects on later
immunity and overall health status (96). In this regard,
probiotics, which have the potential to restore the intestinal
microbiota balance, may add to prevent the development of
chronic immune-mediated diseases (99). If so, this may be
explained by epigenetic mechanisms elicited by probiotics
through the production of short-chain fatty acids (95).
Analysing the effects of LBW related to childhood family,
neighbourhood and socio-demographic conditions on
disease onset in adulthood clearly showed that LBW
increased the risk of asthma, hypertension, type 2 diabetes
mellitus and cardiovascular disease stroke, and heart attack
with ORs by age 50 between 1.51 and 2.16 (100). When
compared to normal birth weight, LBW has long-lasting
effects on chronic diseases in children; at age 14, there were
no differences between ages 8 and 14, but the rate of
obesity increased (99). After birth, maternal-child feeding
patterns may also promote overweight and eating disor-
ders. However, feeding strategies were associated with
reduced body weight rather than child overweight (101).
In light of these ﬁndings, it is fundamental to monitor
early life growth of children and the associated changes in
their body composition. Fat and FFM increase rapidly
during gestation and infancy, but the majority of studies
have relied upon serial measurements of weight, length,
and head circumference to assess growth with very little
information regarding the composition and the quality of
the fat and FFM compartments of the body. Because abso-
lute weight change has limited utility in the identiﬁcation of
infants at risk of later adverse health outcomes that stem
from elevated adiposity, and/or reduced FFM, better accu-
rate and precise body composition assessment techniques
are needed to evaluate the quality of the body mass during
this key period of life (102).
At birth and normal weights (i.e. about 3,500 g for boys
and 3,300 g for girls), normal FM is around 480–500 g or
14–15% of body weight (103). Concomitantly, the hydra-
tion of FFM is about 80% with a protein content of 15%
(103,104). The neonate’s later risk of obesity is then deter-
mined by the presence of gestational diabetes in the mother,
parental obesity, ethnic background, high birth weight as
well as rapid early growth, which deserve a special consid-
eration (105).
Age-related changes in fat and muscle: relationship with
bone and fracture risk
Marjolein Visser
Aging is associated with metabolic, physiologic and func-
tional impairments, in part through age-related changes in
body composition. Across the lifespan, body weight gener-
ally increases until age 80 after which a decline is observed
(106). Even when body weight remains stable in old age,
changes in the composition of soft tissues can be detected.
Changes in body composition with aging relate to body fat
and individual fat depots, skeletal muscle mass, and bone
mineral content. Body weight, fat and muscle mass are
related to bone mineral content and fracture risk. Longitu-
dinal data show mean weight gains in groups up to 60
years, whereas older age groups are more frequently char-
acterized by weight losses (107). The rate of weight gain
decreases from 20 to 60 years, whereas the rate of weight
loss increases from about 2 kg/11 years to more than
5 kg/11 years in subjects above 80 years (107). Weight loss,
but not weight gain, was associated with increased mortal-
ity among older men and women (108). People who lost
weight had a higher mortality rate compared with those
who were weight stable, with similar associations found for
cardiovascular and non-cardiovascular mortality (108).
Measurements have been performed in large prospective
cohort studies conducted in older adults that have used
dual-energy X-ray absorptiometry and/or CT or MRI to
assess age-related changes in FM, muscle fat inﬁltration
and skeletal muscle mass. The total amount of body fat
increases until 75–80 years, after which a decline is
observed which seems to parallel the decline in body weight
in very old age (109). Skeletal muscle and bone masses
decreased, and detailed analyses showed a decrease in skel-
etal muscle mass but an increase in muscle fat inﬁltration
(or intramuscular adipose tissue, IMAT) and VAT (110).
Even though total body fat tends to decline in very old age,
the inﬁltration of fat into the muscles seems to continue
with relative changes between 15 and 30% (in women and
men, respectively; 111). With age, fat also accumulates in
vertebral bone marrow (112), and bone marrow fat content
is related to lower bone mineral content at spine, hip, and
femoral neck, and thus osteoporosis and prevalent verte-
bral fractures (113,114).
With regard to the lean soft tissue, appendicular skeletal
muscle mass decreases with aging and this decline seems to
accelerate in very old age (110,111,114). Concomitantly,
IMAT increases but subcutaneous fat area in mid-thigh
decreases with weight loss (115). Age-related changes in
muscle mass impact muscle function and the loss of muscle
mass is considered to be a major determinant of strength
loss in aging. An annualized 1% decline in muscle mass
with aging is paralleled by a 3% fall in muscle strength
(116). Thus, the strength decline is much more rapid than
the concomitant loss of muscle mass. The loss of lean mass,
higher baseline strength, lower baseline leg lean mass, and
older age are independently associated with strength
decline in both men and women. However, maintaining or
gaining muscle mass does not prevent aging-associated
declines in muscle strength, suggesting body composition
independent processes in age-related functional impair-
ments (116). All these data give evidence for an age-related
remodelling of body composition with reductions in skel-
etal muscle and corresponding increases in VAT and IMAT.
These changes impact body function.
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In white and black women, lean soft tissue and FM are
both associated with bone mineral density (BMD), whereas
in men lean tissue is the only determinant of BMD (117).
Weight loss and a low body weight increase the risk of hip,
spine and wrist fractures; by contrast, a high BMI decreases
the risk (118–121). However, weight-related fracture risk
may differ between locations with ankle fractures increas-
ing with increasing BMI, but pelvic and rib fractures had a
U-shaped association with an increased risk at low as well
as at high BMIs (118,120). In addition to mass, muscle
density also relates the age-related incidence of fractures:
low thigh muscle attenuation increased the 7-year hip frac-
ture incidence (122).
Sarcopenia parallels osteoporosis. With age above 45
years, the prevalence of osteopenia, osteoporosis and
sarcopenia ll began to increase with prevalences of 56, 12
and 34%, respectively, at ages above 70 years (123). There
are numerous connections between bone and skeletal
muscle as, for example, (i) they share mesodermal origin;
(ii) have overlapping signalling pathways during develop-
ment; (iii) their masses peak around the same time; (iv)
have a shared genetic background; and (v) both respond to
similar anabolic stimuli as well as mechanical forces
(123,124). At the cellular level, sarcopenia is characterized
by a loss in myocyte number, a decrease in myoﬁbrillar
protein content, and mitochondrial dysfunction.
Inﬂammation and reduced anabolic stimuli are among
other factors to explain sarcopenia. Abnormalities in
growth hormone IGF1 secretion and signalling may add to
both sarcopenia and osteoporosis (125). In muscle, these
abnormalities result in increased myocyte apoptosis,
decreased myoﬁbre cross-sectional area and increased
expression of proteolytic genes. Concomitantly, low activ-
ity of the growth hormone-IGF1-axis adds to delayed
mineralization, impaired osteoblast differentiation and
proliferation, as well as increased apoptosis in bone cells.
Low mechanical forces due to bed rest, sedentary behav-
iour and low activity impact gravitational loading as well
as muscle contractions (124).
There are correlations between muscle mass and either
bone mass and bone quality (123,126,127). As to muscle–
bone crosstalks, muscle secretes myokines, e.g. myostatin,
leukaemia-inhibitory factor, IL-6 and IL-7, IGF1, ﬁbroblast
growth factor (FGF23). Besides its effects on the muscle
itself, myostatin, a strong regulator of muscle mass in
response exercise and muscle damage, also has an effect
on bone mass (128). In humans, myostatin gene
polymorphisms are associated with peak bone mass. In
addition in mice, overexpression of the myostatin pro-
peptide increases BMD. Epidemiological data also showed
an increased risk of falls and fractures with decreasing
muscle mass (128,129). However, when compared with
muscle mass, muscle strength seems to be the more impor-
tant determinant of falls and fractures (130).
Conclusions
The presentations given at the occasion of the 12th IASO
Stock Conference in 2013 in Hamburg, Germany, supported
Stocks’ view that integration of research ideas about simi-
larities and extremes in obesity and cachexia beneﬁts future
understanding. Body composition data are interpreted
within broader contexts of intermediary metabolism and
inﬂammation by taking into account the relationships
between organs and tissues rather than their individual
masses per se only. Communication is brought about by
numerous crosstalks between organs and tissues, which are
related to their masses as well as their functions. It is
tempting to speculate that changes in body composition
with weight changes (i.e. either weight gain resulting in
overweight and obesity or voluntary weight loss in response
to diet or involuntary weight loss in cancer patients leading
to cachexia) go together with and partly result from altered
or even disturbed crosstalks between organs and tissues.
Because body composition is not ﬁxed throughout life, a
functional body composition approach including (i) the
masses of organs and tissues, (ii) between-organ/tissue mass
relationships, and (iii) between organ and between tissue
crosstalks should become part of a lifetime approach in
humans. This will provide a better understanding of trajec-
tories of organ/tissue masses and their related functions and,
thus, add to future modelling as a reference of normal
integrative physiology throughout life. This will again serve
as a background for understanding extremes like obesity
and cancer cachexia. Then, understanding obesity and
cachexia is more about their differences to models and
references rather than the issue itself.
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